# Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy

Source: https://onco.cc/trials/nct03315364/  
OnCo record `nct03315364` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Oral paclitaxel in advanced solid tumours, run by Daehwa Pharmaceutical Co., Ltd., active and no longer recruiting.

## Summary

Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy is a phase 2/3 interventional study registered as NCT03315364 by Daehwa Pharmaceutical Co., Ltd., with 549 participants enrolled, started 2017-12-18 and due to reach its primary completion in 2024-02-19. Interventions recorded: Oral paclitaxel and Paclitaxel injection.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03315364
- Phase: 2/3
- Setting: A Multinational, Multicenter, Open-label, Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of Liporaxel® (Oral Paclitaxel) Compared to Taxol® (IV Paclitaxel) as First-line Therapy in Patients With Recurrent or Metastatic HER2 Negative Breast Cancer
- Sponsor: Daehwa Pharmaceutical Co., Ltd.
- Enrolled: 549

## Sources

- ClinicalTrials.gov NCT03315364: https://clinicaltrials.gov/study/NCT03315364

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Daehwa Pharmaceutical](https://onco.cc/companies/daehwa-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct03315364.json